Induced Sputum Collection in COPD Patients With and Without a Vibroacoustic Device

Exclusion criteria

• . Any clinically relevant disease or condition which, in the opinion of the investigator, may significantly compromise participant safety, affect study outcomes, or prevent adherence to the protocol. Explicitly excluded is cystic fibrosis or interstitial lung disease.
• . Any condition that, as judged by the investigator, constitutes a contraindication or safety concern for the application of vibroacoustic chest therapy. This includes, but is not limited to:
• . Initiation or discontinuation of mucolytic or expectorant agents (e.g., N-acetylcysteine, ambroxol) within 14 days prior to Visit 1 or between study visits. Participants on stable chronic mucolytic therapy (unchanged regimen for at least 4 weeks prior to Visit 1) may be enrolled provided they maintain the same regimen throughout the study.
• . Treatment with systemic corticosteroids or biological therapies within 6 months prior to screening
• . Treatment with antibiotics within 2 months prior to screening
• . Lower respiratory tract infection within 4 weeks prior to screening
• . Upper respiratory tract infection within 2 weeks prior to screening
• . History of drug or alcohol abuse within 12 months prior to screening